CT041

Claudin18.2-targeted CAR-T cell therapy · CARsgen Therapeutics Co., Ltd.

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for CT041, covering 2024-05-28 to 2025-10-01. Get the full timeline:

Most recent: Clinical Trial Update: To Evaluate the Efficacy of CT041 in Sequential Treatment After First-line Treatment of Advanced Gastric/Esophagogastric Junction Adenocarcinoma

See pricing